Analytical protein aggregate separation without a column
System can achieve separations with higher resolution, reproducibility and recovery then has previously been possible.
Postnova Analytics announces the AF2000 MALS - a new temperature controlled Flow Field-Flow Fractionation MALS system developed to provided unmatched separation, characterization and fractionation of biopharmaceutical proteins.
The AF2000 MALS employs a similar setup to a traditional GPC-MALS system but avoids the limitations of column-based chromatographic separations. In the AF2000 MALS system the liquid chromatography column is replaced by a proprietary separation channel technology that retains molecules based only on size and by the influence of a cross flow as a separation force. Because of the unique design of the system and the absence of any stationary phase, separation on the AF2000 MALS is achieved without exerting shear forces and stress on the proteins and aggregates being separated.
Incorporating Multi-Angle Light Scattering (MALS) and Asymmetric Flow Field-Flow Fractionation (AF4) the AF2000 MALS offers separation over a very broad molar mass and particle size range. With the additional benefit of being able to undertake precisely temperature controlled experiments, the AF2000 MALS is able to achieve separations with higher resolution, reproducibility and recovery then has previously been possible.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...